[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"NYU Langone Health\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":548},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,242,0,25,[9,41,63,94,123,153,174,195,213,233,253,275,299,319,342,362,381,399,419,436,452,468,491,510,529],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100651992","stereotactic-mr-adaptive-radiation-therapy-for-early-stage-renal-cancer-100651992",false,"NCT07767500","Stereotactic MR-Adaptive Radiation Therapy for Early-stage Renal Cancer","A Phase II Single-Arm Study Evaluating Toxicity, Outcomes, and Dosimetry Using an MR-guided Linear Accelerator for the Treatment of Early Stage Kidney Cancer","SMARTER","Inclusion Criteria:\n\n1. Patients at or over 18 years old.\n2. Patients may enter the study if they are diagnosed with bilateral kidney cancer, recurrent kidney cancer, or if they have previous or current history of a another primary cancer, given all other inclusion criteria met.\n3. Have a pathologically confirmed diagnosis of renal cell carcinoma (RCC) of any histology, or radiographic diagnosis if biopsy is not clinically indicated, consistent with standard clinical practice where imaging findings provide sufficient diagnostic certainty. In such cases, biopsy may not be required to avoid additional procedural risk; however, inclusion of patients without histologic confirmation may introduce some diagnostic uncertainty, which will be considered in the interpretation of study results.\n4. Patients must be deemed a suboptimal surgical or ablation candidate, as determined by the patient's primary urologist at NYU Langone Health and confirmed by multidisciplinary consensus, or may be individuals who decline surgery or ablation following appropriate clinical evaluation and discussion..\n\n   o At or before the time of enrollment, a note documenting multidisciplinary consensus supporting active treatment will be recorded in the patient's chart.\n5. Tumor stage of cT1a-b, cN0, M0 (i.e. less than 7 cm in greatest dimension).\n6. Be technically and anatomically appropriate for MRI-guided radiation therapy, as determined by patient's primary radiation oncologist.\n\n   o Factors considered will include distance between tumor and bowel, tumor movement with respiration as assessed by 4-dimensional (4D) imaging, and prior radiotherapy in close proximity to treatment which would lead to high dose overlap from the prior radiation fields.\n7. Have Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n8. Have life expectancy of 2 years or more.\n\nExclusion Criteria:\n\n1. An MRI contraindication (e.g. severe claustrophobia or MRI-incompatible device). In the event of mild claustrophobia, patients will be permitted to take anti-anxiety medication as required for simulation and treatment.\n2. A pre-treatment estimated glomerular filtration rate \\\u003C 30 cc\u002Fmin.\n3. Visceral, nodal, or bony metastatic disease.\n4. Is pregnant or expecting to conceive within the projected duration of the trial at the screening visit.\n5. Pregnant or breastfeeding individuals, or individuals of childbearing potential who have a positive pregnancy test at screening or prior to radiation treatment initiation.\n6. Individuals of childbearing potential who are unwilling to use one highly effective method of contraception and one additional effective method of contraception, or abstain from heterosexual intercourse, during study participation and for 6 months after completion of study therapy.\n7. Previous high dose radiation treatment to an overlapping area.\n8. Has a diagnosis of active scleroderma, lupus, or other rheumatologic disease which in the opinion of the treating radiation oncologist precludes safe radiation therapy.\n9. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n10. Is on systemic therapy that is reasonably expected to modify radiation sensitivity and cannot be stopped for a sufficient washout period to allow for radiation treatment.","ALL","18 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this study is to investigate the use of an MR-guided linear accelerator to treat early stage renal cancer patients, considered inoperable or in patients declining surgerys. The study will collect efficacy, toxicity, and dosimetry data and assess the degree of improvement provided by this treatment technique. The primary objective is to evaluate whether magnetic resonance imaging (MRI)-guided radiation therapy (MRgRT) for primary renal cancer has an improved toxicity profile relative to conventional computed tomography (CT) based radiation therapy, as measured by the frequency of grade 2+ adverse events following MRgRT as per Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.",[28],"Primary Renal Cancer","RECRUITING","2026-08-19",{"date":32,"type":33},"2026-08-21","ACTUAL",{"date":30,"type":33},{"date":36,"type":22},"2030-10",{"name":38,"class":39},"NYU Langone Health","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":18,"minAge":19,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100632005","high-resolution-pharyngeal-manometry-hrpm-biofeedback-100632005","NCT07508059","High Resolution Pharyngeal Manometry (HRPM) Biofeedback","Assessing the Impact of Biofeedback on Task Performance With Swallowing Maneuvers in Healthy Young Adults Using High Resolution Pharyngeal Manometry (HRPM)","Inclusion Criteria:\n\n1. Participants must be independent community dwelling adults.\n2. Participants must be between the ages of 18-40 years old.\n3. Willingness to consent and participate in the study procedures.\n4. No reported dysphagia or difficulty swallowing evidenced by an EAT-10 Score \\\u003C3.\n\nExclusion Criteria:\n\n1. Known structural or neurological causes of dysphagia (e.g., stroke, brain injury, or head\u002Fneck cancer).\n2. Recent or remote history of swallowing therapy; familiarity with swallowing maneuvers from relevant coursework as applicable (i.e., speech language pathology students).",true,"40 Years",{"count":51,"type":22},50,[25],"The purpose of this study is to quantify the added benefit of visual biofeedback from High Resolution Pharyngeal Manometry (HRPM) for swallowing rehabilitation. Primary aims including assessing changes in swallowing biomechanics (pressure generation, timing) during swallow maneuvers with and without HRPM visual biofeedback. Secondary aim includes participant attitudes related to visual biofeedback and the experience of HRPM.",[55],"Healthy",[57],"Swallow",{"date":32,"type":33},{"date":30,"type":33},{"date":61,"type":22},"2027-05-01",{"name":38,"class":39},{"id":64,"slug":65,"hasResults":12,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":23,"phases":73,"briefSummary":74,"conditions":75,"keywords":79,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},"100498904","harm-reduction-services-100498904","NCT05776316","Harm Reduction Services","Culturally Response Integrated Harm Reduction Services for Black and Latinx People Who Use Drugs","HRS","Inclusion Criteria:\n\n* at least 18 years of age\n* self-identified as misusing opioids +\u002F- other substances (stimulants) in the past 30 days, confirmed by interview using DSM-5 criteria\n* English or Spanish speaking\n* able to provide informed consent.\n\nExclusion Criteria:\n\n* inability to provide informed consent or participate in the study procedures as proposed in the consent\n* active suicidal or homicidal ideation or an unstable psychotic disorder (schizophrenia, schizoaffective disorder) or mood disorder (bipolar disorder, severe major depressive disorder)\n* an unwillingness to be randomized.\n* are prisoners",{"count":72,"type":22},200,[25],"The purpose of this study is to assess whether an integrated harm reduction intervention (IHRI), compared to harm reduction (HR) services as usual, will improve harm reduction service utilization among Black and Latinx people who use drugs (PWUD).",[76,77,78],"Drug Use","Substance Abuse","Mental Illness",[80,81,82,76,83,84,85],"Harm Reduction","Latinx\u002FHispanix","Black\u002FAfrican American","Cocaine","Opioids","Methamphetamines",{"date":87,"type":33},"2026-08-20",{"date":89,"type":33},"2024-11-25",{"date":91,"type":22},"2028-03-28",{"name":38,"class":39},3,{"id":95,"slug":96,"hasResults":12,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":104,"briefSummary":106,"conditions":107,"keywords":110,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":40},"100638545","phase-1-psilocybin-as-a-novel-therapy-for-residual-anhedonia-100638545","NCT07607938","Psilocybin as a Novel Therapy for Residual Anhedonia","Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Able to provide voluntary signed and dated informed consent.\n* Females of childbearing potential (FOCBP) must agree to practice an effective means of birth control throughout the duration of the trial\n* Males who have FOCBPs as partners must agree to practice an effective means of birth control throughout the duration of the trial\n* State willingness to comply and be available for all study requirements, including psychological, cognitive, imaging and procedural evaluations for the duration of the study\n* Meet DSM-5 criteria for major depressive disorder (MDD)\n* Screening Dimensional Anhedonia Rating Scale (DARS) total score of \\\u003C 28.5 points\n* Have an identified support person\n* Agree to refrain from taking all non-prescription medications and supplements (nutritional and herbal) for at least 1 week prior to the IP administration session unless approved by the Investigator.\n\nExclusion Criteria:\n\n* Inability to speak and understand English sufficiently to complete informed consent and study procedures.\n* Inability to provide informed consent.\n* Women who are pregnant or who intend to become pregnant or nurse during the study duration.\n* Prior exposure to classic psychedelics (i.e., psilocybin, LSD, ayahuasca, and\u002For mescaline) within the past 1 year.\n* Current or previous psychiatric conditions that meet DSM-5 criteria for psychotic disorders (i.e., schizophrenia, schizoaffective disorder, MDD with psychosis), bipolar 1 or 2 disorder, or current diagnosis of active substance use disorder.\n* Have active suicidal ideation with intent, based on Columbia-Suicide Severity Rating Scale (C-SSRS assessment (severity score \\> 3) at the Screening visit, confirmed by the Investigator.\n* Have made a medically significant suicide attempt (i.e., one that had a significant possibility of causing death or permanent harm in the absence of intervention) within the past 12 months, based on Screening C-SSRS assessment and confirmation by the Investigator.\n* Immediate family history (i.e., parents, full siblings, or half siblings) with known or suspected psychotic disorder.\n* Presence of medical conditions that may confound results of imaging study or that are contraindications to or psilocybin exposure (i.e., neurological, renal, hypertension, metabolic or cardiovascular disease or pregnancy);\n* Presence of contraindications to MRI scanning (implantable devices, bone hardware, various IUD).\n* Participants who received electroconvulsive therapy (ECT), trans magnetic cranial stimulation (TMS), and\u002For ketamine in the past 90 days.\n* Has any other physical or psychological symptom, medication, or other relevant finding prior to randomization that, based on the clinical judgment of trial personnel, would make a participant unsuitable for the trial.\n* Are unable or unwilling to discontinue taking any protocol-prohibited medications and supplements.","65 Years",{"count":103,"type":22},90,[105],"PHASE1","This study is for adults with major depressive disorder (depression) who are currently taking an SSRI or SNRI antidepressant but continue to experience anhedonia (reduced interest or pleasure) and emotional blunting.\n\nThe study will test whether a single 25 mg dose of psilocybin, compared with placebo, can improve these symptoms and improve the function of brain circuits involved in reward and motivation. Researchers will measure changes using brain imaging (fMRI) and clinical questionnaires, including the Dimensional Anhedonia Rating Scale (DARS).",[108,109],"Anhedonia","Emotional Blunting",[111,112,113,108,109,114],"SSRI","SNR","Depression","Psilocybin","NOT_YET_RECRUITING","2026-08-18",{"date":87,"type":33},{"date":119,"type":22},"2026-09",{"date":121,"type":22},"2030-09-30",{"name":38,"class":39},{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":18,"minAge":131,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":134,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":152},"100500678","phase-3-effects-of-stopping-hydroxychloroquine-in-elderly-lupus-disease-100500678","NCT05799378","Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease","A Phase III, Randomized, Double-Blind Placebo-Controlled, Non-Inferiority, Multi-Center Study of the Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease","SHIELD","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Age ≥ 55 years at time of enrollment\n* Normal OCT and VF assessment within 6 months of screening visit\n* Ability to take oral medication\n* Have established SLE (≥ 4 ACR criteria or SLICC criteria or ≥ 10 points by EULAR criteria, SLE diagnosed at least seven years ago)\n* Stable disease at screening visit by attaining DORIS remission (meeting all criterion listed below) and not on any immunosuppressants.\n\n  * Criterion 1: Clinical SLEDAI= 0\n  * Criterion 2: SELENA-SLEDAI PGA ≤ 0.5 (on a scale from 0-3, where 0 is no disease activity and 3 is maximum disease activity)\n  * Criterion 3: Current prednisolone (or equivalent corticosteroid) dose ≤ 5 mg daily\n* No moderate or severe flares one year prior to screening\n* Taking ≥ 200 HCQ daily for ≥ 7 years\n\nExclusion Criteria:\n\n* Any patient that does not attain stable disease status by DORIS\n* Ophthalmologic evidence of retinopathy (these patients would be advised to discontinue HCQ and therefore unethical to randomize for this study)\n* Clinical SLEDAI \\> 0\n* Taking \\> 5 mg\u002Fday prednisone\n* Taking any immunosuppressive drugs or biological agents (including: methotrexate, azathioprine, mycophenolate mofetil, mycophenolic acid, leflunomide, cyclosporine, cyclophosphamide, tacrolimus, rituximab, and belimumab)\n* Any reason the treating rheumatologist is concerned about ongoing activity not captured by SLEDAI\n* HCQ level \\\u003C 100 ng\u002Fml as this would support noncompliance and less reliance on HCQ to control activity\n* Patient unwilling or unable to comply with study procedures for any reason\n* Any indications of potentially diminished capacity, such as a diagnosis of dementia or cognitive impairment (including, but not limited to stroke-related cognitive impairment)","55 Years",{"count":133,"type":22},330,[135],"PHASE3","Hydroxychloroquine (HCQ) is a systemic lupus erythematosus (SLE) medication that has been very effective in reducing lupus disease activity and keeping patients stable with reduced symptoms. Despite a track record of safety with regard to infection compared to traditional immunosuppressive agents, the risk of HCQ retinal toxicity escalates with continued use. Evaluation using sensitive standard of care approaches suggests nearly a third of patients accrue retinal damage. Data are needed to accurately weigh the balance between accumulating ocular exposure of HCQ versus the risk of disease flare in a population that may have more inactive disease than younger patients. The purpose of this trial is to address the safety of withdrawal of HCQ in SLE patients \\>=55 years old. The central hypothesis is that HCQ can be safely discontinued in stable\u002Fquiescent patients assessed by validated disease activity and flare instruments in the context of serologic, cytokine and transcriptomic profiling. Patients will be randomized to either the placebo or active arm and followed every 3 months for one year to assess disease activity and flares.",[138],"Systemic Lupus Erythematosus",[140,141,142,143,144,145],"Hydroxychloroquine","systemic lupus erythematosus","elderly lupus disease","lupus","sle","plaquenil",{"date":87,"type":33},{"date":148,"type":33},"2024-06-27",{"date":150,"type":22},"2029-06-30",{"name":38,"class":39},12,{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":160,"minAge":19,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":23,"phases":163,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":171,"leadSponsor":173,"locationsCount":40},"100652100","pilot-trial-of-fetoscopic-endoluminal-tracheal-occlusion-feto-in-fetuses-with-severe-cdh-100652100","NCT07767825","Pilot Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Fetuses With Severe CDH","Pilot Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Fetuses With Severe Congenital Diaphragmatic Hernia (CDH)","Inclusion Criteria:\n\n1. Provision of a signed and dated informed consent form\n2. Pregnant individuals age 18 years and older\n3. Singleton pregnancy\n4. A normal karyotype with confirmation by culture results, CMA with non-pathologic variants, whole exome or genome sequencing (WES or WGS).\n5. Isolated left CDH with severe pulmonary hypoplasia with o\u002Fe LHR less than 25% with liver up (measured at 18 weeks 0 days to 29 weeks 5 days of gestation)\n6. Isolated right CDH with severe pulmonary hypoplasia with o\u002Fe LHR equal or less than 30% with liver up (measured at 18 weeks 0 days to 29 weeks 5 days of gestation)\n7. Gestational age at FETO procedure 27 weeks 0 days to 29 weeks 6 days as determined by clinical information (LMP) and evaluation of first ultrasound\n8. Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study\n9. Willing to reside within a 30-minute distance of the NYULH in the time period between the FETO placement procedure and the balloon retrieval procedure, and ability to maintain follow-up appointments\n10. The subject has a support person (e.g., spouse, partner, friend, parent) who is available to stay with her for the duration of the pregnancy near NYULH.\n11. Willing to comply with restrictions of daily living, including inability to exercise, have intercourse, or return to work\n12. Meets psychosocial criteria\n\nExclusion Criteria:\n\n1. Natural rubber latex allergy\n2. Additional fetal anomaly and chromosomal abnormalities, associated anomalies recognized to alter survival prognosis (i.e., congenital heart disease) or presence of an underlying genetic syndrome (i.e., Fryns) by ultrasound, MRI or echocardiogram at the fetal treatment center.\n3. Signs of preterm labor, cervix shortened to ≤20 mm at enrollment or at 24 hours prior to FETO balloon insertion procedure) or a uterine anomaly strongly predisposing to preterm labor.\n4. Maternal contraindication to fetoscopic surgery or severe maternal medical condition in pregnancy\n5. History of incompetent cervix with or without cerclage\n6. Placental abnormalities (previa, abruption, accreta, chorioangioma) known at time of enrollment\n7. Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy\n8. Maternal HIV, Hepatitis-B, Hepatitis-C status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis status is unknown, the patient must be tested and found to have negative results before enrollment\n9. Uterine anomaly such as large or multiple fibroids or mullerian duct abnormality\n10. There is no safe or technically feasible fetoscopic approach to balloon placement\n11. Participation in another intervention study that influences maternal and fetal morbidity and mortality\n12. Any other condition which, in the opinion of the investigator, would compromise safety, feasibility or impede compliance.\n13. Bilateral CDH, isolated left sided CDH with o\u002Fe LHR \\>\u002F= 25% and isolated right sided CDH \\>30%\n14. No intrathoracic liver herniation","FEMALE",{"count":162,"type":22},10,[25],"The purpose of this pilot study is to evaluate the feasibility of using Fetoscopic Endoluminal Tracheal Occlusion (FETO) in 10 pregnant individuals carrying fetuses with severe congenital diaphragmatic hernia (CDH). FETO surgery will be performed at 27 weeks - 29 weeks and 6 days of gestation, and the fetoscopic removal of the balloon will be performed at 34 weeks - 34 weeks and 6 days of gestation. The primary endpoint is successful placement and removal of the balloon.",[166],"Severe Congenital Diaphragmatic Hernia","2026-08-14",{"date":169,"type":33},"2026-08-17",{"date":119,"type":22},{"date":172,"type":22},"2031-09",{"name":38,"class":39},{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":18,"minAge":181,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":192,"leadSponsor":194,"locationsCount":40},"100652234","phase-1-novel-irrigation-solution-for-colonoscopy-visualization-pilot-100652234","NCT07769905","Novel Irrigation Solution for Colonoscopy Visualization Pilot","A Pilot Evaluation of a Novel Irrigation Solution to Enhance Visualization During Colonoscopy","Patient Inclusion Criteria:\n\n1. Between 45 to 75 years of age\n2. Currently receiving gastroenterology or primary care at NYU Langone Hospital\n3. Capacity and willingness to provide consent\n4. Undergoing a screening colonoscopy\n\nProvider Inclusion Criteria:\n\n1. Faculty gastroenterologist at NYU Langone Ambulatory Care Center\n2. At least 18 years of age\n3. Willingness to provide consent\n\nPatient Exclusion Criteria:\n\n1. Under 45 years or over 75 years of age\n2. Known allergy to blue dye, peppermint and\u002For simethicone\n3. Current use of antispasmodics or anti-flatulance agents\n4. Pregnancy: This exclusion is based on standard clinical practice and safety considerations, as colonoscopy is not typically performed during pregnancy except in urgent circumstances. Accordingly, inclusion of pregnant individuals in this elective, pilot feasibility study would not be clinically appropriate or scientifically justified.\n\nProvider Exclusion Criteria:\n\n1\\. Not a gastroenterology provider at NYULH","45 Years","75 Years",{"count":184,"type":22},35,[105],"The purpose of this study is to assess the provider experience with a novel colonoscopy irrigation solution and determine the feasibility of introducing this solution into the endoscopy unit and assess efficacy on a small scale prior to a larger study. Specifically, the study will assess mucosal visibility, colonic spasm, and intralumenal bubbles observed during colonoscopy.",[188],"Colonoscopy","2026-08-13",{"date":116,"type":33},{"date":119,"type":22},{"date":193,"type":22},"2027-03",{"name":38,"class":39},{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":23,"phases":203,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":207,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":40},"100652132","hypoxia-targeted-radiotherapy-boost-for-gbm-100652132","NCT07769918","Hypoxia-targeted Radiotherapy Boost for GBM","HYPO2-BOOST GBM Trial: Hypoxia-targeted Radiotherapy Boost for GBM","Inclusion Criteria:\n\n1. Willing and able to provide written informed consent.\n2. ≥18 years of age.\n3. All suspected GBM patients including newly diagnosed and recurrent GBM who are undergoing resection (Phase 1). Or all suspected newly diagnosed or recurrent GBM being treated with radiation where there is still visible tumor) (Phase 2)\n4. Participants with a history of prior malignancies and previous LITT are permitted to enroll.\n5. KPS \\> 50.\n6. Subjects must have adequate liver and kidney function, defined as:\n7. Liver transaminase levels ≤2.5 × the upper limit of normal (ULN); total bilirubin ≤1.5 × ULN, except in subjects with Gilbert's Disease in whom total bilirubin ≤5 × ULN is allowed.\n8. Creatinine clearance ≥60 mL\u002Fmin measured from a 24-hour urine collection or calculated based on the Cockcroft-Gault formula OR serum creatinine ≤ULN.\n9. Female subjects of childbearing potential and male subjects with female partners of childbearing potential must be willing to avoid pregnancy. Female subjects of childbearing potential who are undergoing RT or who are partners to male subjects in the study should avoid sexual activity or use a highly effective method of birth control during sexual intercourse. Acceptable, highly effective methods of birth control include intrauterine device (IUD)\u002Fintrauterine hormone releasing system (IUS), bilateral tube occlusion, vasectomized partner, combined (estrogen and progesterone containing) or progesterone-only hormonal contraceptives (oral, intravaginal, transdermal, injectable).\n10. Patient with recurrent tumor amendable to reirradiation and is at least 3 months from end of prior brain radiation therapy\n\nExclusion Criteria:\n\nSubjects must not meet any of the following criteria to be eligible for study participation:\n\n1. Subjects with bone marrow impairment as evidenced by hemoglobin \\\u003C8.0 g\u002FdL, neutrophil count \\\u003C1.5 × 109\u002FL, or platelets \\\u003C100 × 109\u002FL.\n2. Significant cardiac conduction abnormalities, including a history of long corrected QT (QTc) interval syndrome (\\>450 msec per Fridericia's formula) and\u002For pacemaker, or impaired cardiovascular function such as New York Heart Association classification \\>2 at screening.\n3. Subjects who are pregnant or breast-feeding.\n4. Contraindication to temozolomide\n5. Severe headache, rapidly progressive neurologic decline, objective neurologic manifestations of uncal herniation, depressed level of consciousness",{"count":7,"type":22},[25],"The purpose of this study is to evaluate the use of dynamic contrast-enhanced MRI (DSC-MRI) to identify and target hypoxic tumor regions in glioblastoma (GBM). The study is divided into two phases: Phase 1 will focus on biologic validation in newly diagnosed GBM patients, while Phase 2 will assess the clinical implementation of DSC-MRI-guided radiotherapy in recurrent or postoperative GBM patients. The primary endpoints are the validation of DSC-MRI in identifying hypoxic regions and assessing the safety and efficacy of radiation therapy based on these findings.",[206],"Glioblastoma (GBM)",{"date":116,"type":33},{"date":209,"type":22},"2026-09-01",{"date":211,"type":22},"2029-06-01",{"name":38,"class":39},{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":23,"phases":222,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":227,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":40},"100559818","cd34-selected-stem-cell-for-poor-graft-function-or-graft-failure-100559818","NCT06569082","CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure","CD34+ Selected Donor Cell Boost for Management of Poor Graft Function or Primary or Secondary Graft Failure Following Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Recipient of allogeneic transplantation, adult ≥18 years, from any type of donor including matched related, matched unrelated, mismatched related or mismatched unrelated or haploidentical donor transplant.\n* Documented evidence of graft dysfunction or failure (a-c):\n\n  1. Primary graft Failure: Graft failure is defined as failure to achieve neutrophil engraftment by day +28 or lack of donor chimerism \\> 50% by day 45 not due to the underlying malignancy;\n  2. Poor graft function is defined by at least 2 of the following 3 criteria: Hemoglobin \\\u003C 8 g\u002FdL, ANC \\\u003C 0.5x109\u002FL, and platelets \\\u003C 20x109\u002FL. The cytopenia must be unexplained (such as by disease relapse) and unresponsive to hematopoietic growth factors and must last at least 4 weeks;\n  3. Secondary graft failure is defined as poor graft function associated with donor chimerism \\\u003C 5% after initial engraftment\n* Transplanted donor availability\n* Negative pregnancy test within seven (7) days of product infusion for women of childbearing potential.\n\nExclusion Criteria:\n\n* Graft failure due to disease relapse or evidence of disease relapse or progression\n* Donor unavailable or unable to collect peripheral HPC by apheresis\n* Responsive to conventional measures (such as, hematopoietic growth factor)\n* Allergic reaction to murine proteins or iron dextran\n* Women of childbearing potential with positive serum HCG",{"count":221,"type":22},21,[25],"The proposed trial is a single arm, non-randomized, single center pilot study utilizing CliniMACS CD34 Reagent System for patients following allogeneic hematopoietic stem cell transplant (HSCT) requiring treatment of graft dysfunction or failure.",[225,226],"Graft Failure","Poor Graft Function",{"date":169,"type":33},{"date":229,"type":33},"2024-10-31",{"date":231,"type":22},"2035-08",{"name":38,"class":39},{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":23,"phases":242,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":40},"100614356","adaptive-dietary-intervention-adi-for-asian-americans-with-type-2-diabetes-100614356","NCT07278531","Adaptive Dietary Intervention (ADI) for Asian Americans With Type 2 Diabetes","Adaptive Dietary Intervention (ADI) Leveraging Continuous Glucose Monitoring for Asian Americans With Type 2 Diabetes","Inclusion Criteria:\n\n* Eligible participants (N=120; 60 Chinese Americans and 60 Vietnamese Americans)\n* Community-dwelling adults aged ≥ 18 with independent living;\n* Diagnosed with T2D;\n* Hb1Ac\\>7.0%\n* Self-identified as first- or second-generation Chinese or Vietnamese immigrants;\n* Able to communicate in English, Chinese, or Vietnamese. We will focus on Mandarin-, Cantonese- or English-speaking Chinese Americans because the two best-known and most-spoken variants of Chinese are Mandarin and Cantonese, who use the same writing system;\n* Have a smartphone, iPad, tablet, or Apple watch\n\nExclusion Criteria:\n\n* Taking hypoglycemia agents (e.g., insulin and sulfonylureas) with the major side effect of hypoglycemia that need close monitoring the occurrence of hypoglycemia to adjust\u002Freduce medications to avoid future hypoglycemia.\n* Taking medications that impede weight loss (e.g., prednisone) within the last 3 months.\n* Currently pregnant, breastfeeding, or contemplating pregnancy within the next 6 months.\n* Have serious physical complications (e.g., severe neuropathy cardiovascular disease, COPD\u002Femphysema, osteoarthritis, or stroke) or mental disease (e.g., schizophrenia, bipolar disorder, manic depressive illness, severe depression, or active substance abuse).\n* Have conditions that restrict diet, such as severe gastroparesis, ulcers, or food allergies. These conditions may need special dietary intervention.\n* Undergoing treatment for cancer, as cancer treatment may impact the outcome of glucose changes.\n* Have marked renal impairment (eGRF\\\u003C45; CKD-3b), as renal impairment may needs special dietary intervention and they also may impact glucose changes.\n* Are taking psychotropic medications that raise blood glucose (e.g., atypical antipsychotics).\n* Are prior or current CGM users including both Dexcom and FreeStyle Libre and plan to continuously use these CGMs in the next 6 months.\n* Are participating in another T2D intervention study.",{"count":241,"type":22},120,[25],"The investigators will examine the feasibility, acceptability, and effect of an adaptive dietary intervention over 24 weeks (12-week intervention, 12-week follow-up) among Asian Americans with Type 2 diabetes. Participants (N=120; 60 Chinese Americans and 60 Vietnamese Americans) will be 2:1 randomized to one of two arms: adaptive dietary intervention or standard of care (SC). The intervention will begin with continued glucose monitoring (CGM) use only during weeks 0-4. At week 4, participants who achieve the glycemic control goal (at least an 8% increase in time in range \\[TIR\\] from baseline) will continue with the CGM alone during weeks 4-12 (\"CGM Alone\"); otherwise, culturally and linguistically adapted glucose excursion minimization (GEM) will be augmented with CGM (\"CGM-GEM\").",[245],"Type 2 Diabetes","2026-08-11",{"date":189,"type":33},{"date":249,"type":22},"2027-02",{"date":251,"type":22},"2028-08-31",{"name":38,"class":39},{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":101,"enrollmentInfo":260,"targetDuration":4,"studyType":23,"phases":261,"briefSummary":263,"conditions":264,"keywords":266,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":272,"leadSponsor":274,"locationsCount":40},"100542916","phase-2-neurobehavioral-mechanisms-of-psilocybin-assisted-treatment-for-aud-100542916","NCT06349083","Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD","Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder","Inclusion Criteria:\n\n1. Are able to provide voluntary informed consent\n2. Have a breath alcohol concentration (BrAC) ≤ 0.01% at screening, as determined by a breath alcohol reading from a calibrated breath alcohol sensor. (Note: this criterion may be re-evaluated within the 30-day screening period.\n3. Are able to read, speak, and understand English, as documented during the informed consent process.\n\n   a. Non-English speaking subjects will be excluded because the study is using only validated English-language versions of assessment instruments.\n4. Are 18 to 65 years old, inclusive, at Screening visit.\n5. Have DSM-5 diagnosis of moderate or severe AUD (using MINI)\n6. Eligible participants must either (a) not currently receiving treatment for alcohol use disorder (AUD), or (b) have been in continuous treatment for AUD for at least 3 months and plan to continue. (Any medications used to treat AUD would need to be discontinued no less than 5 half lives or 14 days (whichever is greater) prior to the IP administration session. Patients who who are completing detoxification from alcohol and do not have plans for follow-up treatment would be eligible to participate in the study after completion of the detoxification program).\n7. Are able and willing to adhere to all study requirements, including attending all study visits and therapy sessions, and completing all assessments.\n8. Have least 4 heavy drinking days (4 or more drinks per day for a woman, 5 or more drinks per day for a man) in the 30 days prior to admission to the screening visit.\n9. Agree to refrain from alcohol use as well as any non-prescribed psychotropic substance or illicit drug use for at least 24 hours prior to investigational product (IP) administration and before each fMRI assessment visit, with the exceptions of nicotine and caffeine. Regarding nicotine, they must agree not to use nicotine for at least 1 hour before and 6 hours following IP administration, and for at least 1 hour before fMRI scans. Regarding caffeine, they must agree to consume approximately their usual amount of caffeine on the morning of Day 0 (prior to IP administration).\n10. Agree to refrain from taking all non-prescription medications and supplements (nutritional and herbal) for at least 1 week prior to the IP administration session unless approved by the Investigator.\n11. Are able to swallow capsules.\n12. If able to become pregnant, have a negative serum pregnancy test at screening.\n13. If able to become pregnant or produce viable sperm (male or female), are willing to use approved contraception for duration of the trial\n14. Able to provide at least 2 locators.\n15. Participants must be able to commit to being sober at the time all treatment sessions and the two fMRI sessions, and to stay sober from the time of the drug administration until the second fMRI session.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation\n2. Any medical condition that would preclude safe participation in the study, including the following, as determined by medical history review, physical examination, electrocardiogram (ECG), and clinical laboratory tests:\n\n   1. Seizure disorder\n   2. Significantly impaired liver function, defined as 1) alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\> 5 × upper limit of normal (ULN); 2) ALT or AST \\> 3 × ULN with concomitant total bilirubin \\> 2.0 × ULN; or 3) ALT or AST ≥ 3 × ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and\u002For eosinophilia.\n   3. Cardiovascular disease including coronary artery disease, angina, history of arrhythmia (unless a successful ablation has been performed), heart failure, history of heart valve replacement, and history of cerebrovascular accident or transient ischemic attack.\n   4. Uncontrolled hypertension with systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\> 90 mmHg. (Note: participants who otherwise meet all eligibility criteria during the screening visit will have 3 opportunities to produce 1 blood pressure reading ≤ 140\u002F90 mmHg (each reading will be collected at least 15 minutes apart). If blood pressure at Screening is consistently elevated (\\> 140\u002F90 mmHg across all 3 attempts), participants may be referred to their medical provider for management of hypertension. Participants may continue study participation if they are able to provide documentation of adequate control (BP \\> 140\u002F90 mmHg) prior to the IP administration session.)\n   5. Resting heart rate \\> 100 bpm (Note: participants will have an opportunity to return once within the 30 day screening window to make 3 additional attempts at a resting heart rate ≤ 100 bpm.).\n   6. Serious ECG abnormalities present on the ECG obtained at the screening visit (e.g., evidence of ischemia, myocardial infarction, QT interval corrected for heart rate \\[QTc\\] prolongation (QTc \\> 0.450 seconds), arrhythmia, or conduction abnormalities that increase the risk of arrhythmia.\n   7. Hyperthyroidism\n   8. Insulin-dependent diabetes\n   9. Any other medical condition which precludes safe participation in the study in the medical opinion of the Investigator. (Note: medical history will be updated on Day 0. Those not meeting the criterion will not be randomized but may be rescheduled once within 14 days if the criterion is likely to resolve within 14 days in the judgement of the Investigator.)\n3. Have any of the following DSM-5 psychiatric disorders, as determined by the MINI and Psychiatric History at the Screening Visit: (Note: psychiatric history will be re-evaluated on Day 0, but the MINI will not be re-administered on Day 0)\n\n   1. Lifetime history of schizophrenia spectrum or other psychotic disorder (including substance or medication-induced psychosis or psychosis due to a co-occurring medical condition).\n   2. Current alcohol withdrawal (CIWA-Ar score \\>7)\n   3. History of mania\n4. Have active suicidal ideation with intent, based on Columbia-Suicide Severity Rating Scale (C-SSRS) (past week severity score \\>3) at the Screening visit, confirmed by the Investigator. (Note: this criterion will be reassessed at each visit that occurs prior to Day 0, and on Day 0 prior to randomization. Participants will be withdrawn if actively suicidal, and appropriate follow-up will be arranged.\n5. Have made a medically significant suicide attempt (i.e., one that had a significant possibility of causing death or permanent harm in the absence of intervention) within the past 12 months, based on Screening C-SSRS assessment and confirmation by the Investigator. (Note: this criterion will be reassessed at each visit that occurs prior to Day 0, and on Day 0 prior to randomization. Participants will be withdrawn if actively suicidal, and appropriate follow-up will be arranged.)\n6. Have a family history (first degree relatives) of schizophrenia, schizoaffective disorder, or bipolar disorder type 1.\n7. Have a history of hallucinogen use disorder.\n8. Have a history of hallucinogen persisting perceptual disorder (HPPD).\n9. Have any use of classic psychedelics in the past 1 year.\n10. Have \\> 25 lifetime uses of classic psychedelics.\n11. Incarcerated or have pending legal action that could prevent participation in study activities.\n12. Are court-mandated to complete treatment or are a prisoner.\n13. Are unable or unwilling to discontinue taking any protocol-prohibited medications and supplements. (A detailed list of exclusionary medications is found in Section 6.5 of the protocol). Current SSRI use is allowed only if the dose has been stable for at least one month at the time of Screening visit. Prohibited medications and supplements must have been stopped for at least 5 elimination half-lives or 14 days, whichever is longer, prior to Day 0 (Note: Psychiatric medications will not be discontinued or changed in order to allow study participation unless such change does not cause any increase in risk to the study participant, in the judgement of the study physician and the prescribing provider. For example, a change in a medication for sleep might be appropriate if a non-exclusionary alternative is available. Any such study-related changes in medication will be documented in a progress note which will include explanation for why the change does not increase overall clinical risk and documentation of the prescribers concurrence with the treatment plan.)\n\n    a. Note that any medication prescribed to the participant for AUD is exclusionary, including FDA-approved medications as well those prescribed off-label, such as topiramate, ondansetron, gabapentin, and varenicline.\n14. Have a known allergy or hypersensitivity to psilocybin or any of the materials contained in the IP used in the study.\n15. Have an allergy, hypersensitivity, or other contraindication that would preclude safe treatment of acute hypertension, anxiety, or psychotic symptoms if necessary during or immediately after the IP Administration Session, using the adjunctive medications used in this study to treat these symptoms (i.e., unable to take captopril and unable to take clonidine; unable to take diazepam; or unable to take olanzapine).\n16. Have any other medical, psychiatric, or psychosocial disorder, symptom, condition, or situation that is likely to interfere with the establishment of rapport, adherence to study requirements, or safe administration of psilocybin or fMRI scanning, based on the judgement of the Investigator.\n17. Inability to safely complete fMRI sessions (MRI screening form), including presence of metallic implants or devices that contraindicate MRI or claustrophobia.\n18. Any history of severe traumatic brain injury (assessed using OSU TBI-ID modified). (Note: If current (past 12 months) mild\u002Fmoderate TBI and CSI score \\>\u002F=12 (for either lifetime month or current month), the PI will determine eligibility.)",{"count":72,"type":22},[262],"PHASE2","This is a double-blind, randomized, placebo-controlled Phase 2 mechanistic clinical trial designed to evaluate the therapeutic neural mechanisms of psilocybin in patients with alcohol use disorder (AUD), and to determine whether further studies are warranted to study the relationship of any such effects to clinical improvement in AUD symptoms. The primary aims are to evaluate the effects of psilocybin on AUD; measures will include 1) fMRI neural activation and functional connectivity, using a well-validated task to characterize neural and subjective response to negative affective and alcohol visual stimuli; 2) alcohol use data (self-report and blood biomarkers); and 3) self-report measures related the NE, IS, and EF domains.",[265],"Alcohol Use Disorder",[267,268],"psilocybin","AUD",{"date":270,"type":33},"2026-08-12",{"date":209,"type":22},{"date":273,"type":22},"2030-05",{"name":38,"class":39},{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":48,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":284,"phases":4,"briefSummary":285,"conditions":286,"keywords":289,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":40},"100650789","young-onset-parkinsons-disease-subtypes-and-pathogenic-mechanisms-100650789","NCT07752355","Young Onset Parkinson's Disease Subtypes and Pathogenic Mechanisms","YOPD","Inclusion Criteria:\n\nYOPD cohort:\n\n1. Male or female 18 years or older (inclusive) of any race and ethnicity\n2. Diagnosis of Parkinson's disease (PD) confirmed by a movement disorder specialist and with an age of onset of less than or equal to the age of 50 years old\n3. Willingness to undergo a skin punch biopsy\n\nLOPD cohort:\n\n1. Male or female 18 years or older (inclusive) of any race and ethnicity\n2. Diagnosis of PD confirmed by a movement disorder specialist and with an age of onset after the age of 50 years\n\nHealthy Control cohort:\n\n1. Male or female 18 years or older (inclusive) of any race and ethnicity\n2. Never been diagnosed with PD as reported by medical history and as assessed by study PI\n\nExclusion Criteria:\n\n1. Diagnosis of atypical parkinsonism (i.e. progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy) or secondary parkinsonism (i.e. normal pressure hydrocephalus, drug-induced parkinsonism).\n2. Clinical history of autoimmune or chronic inflammatory disorder or exposure to chronic immunosuppressant or immunomodulatory medications.\n3. Pregnancy\n4. Dermatological conditions that would prevent performing skin punch biopsies",{"count":283,"type":22},250,"OBSERVATIONAL","Young Onset Parkinson's disease (YOPD) refers to a group of patients in which the disease starts earlier in life (before the age of 50 years) and has a profound impact on most of patient's life. Current knowledge regarding the mechanisms leading to development of Parkinson's disease in younger individuals is lacking, but their understanding is crucial for the successful design of therapeutic strategies and stratifying patients for clinical trials. With this research the investigators aim to clarify the contribution of relevant biological processes in patients with Young onset Parkinson's disease to help understanding disease mechanisms and biomarkers.",[287,288],"Young Onset Parkinson Disease","Parkinson Disease",[287,288,290,291],"Early Onset Parkinson Disease","EOPD","2026-08-10",{"date":270,"type":33},{"date":295,"type":33},"2024-02-28",{"date":297,"type":22},"2028-10-31",{"name":38,"class":39},{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":48,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":23,"phases":308,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":312,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":318},"100491177","leveraging-regulatory-flexibility-for-methadone-take-home-dosing-to-improve-retention-in-treatment-for-opioid-use-disorder-100491177","NCT05675735","Leveraging Regulatory Flexibility for Methadone Take-Home Dosing to Improve Retention in Treatment for Opioid Use Disorder","Leveraging Regulatory Flexibility for Methadone Take-Home Dosing to Improve Retention in Treatment for Opioid Use Disorder: A Stepped-Wedge Randomized Trial to Facilitate Clinic Level Changes","Inclusion Criteria:\n\n* Clinic staff inclusion will include anyone who works at the 10 clinics that the OASAS client data system generates from the quantitative analysis in year one. In years 2-5, clinics chosen by the OASAS client data system will be placed into six cohorts. Only staff from these clinics will be eligible.\n* Patient inclusion will include anyone aged 18 or older who has been receiving take-home methadone for at least 30 days.\n\nExclusion Criteria\n\n• There are no exclusion criteria related to sex\u002Fgender to increase the generalizability of the findings. The investigators will note include children in this study because the treatment system that we are examining largely excludes adolescents and younger children.",{"count":307,"type":22},318,[25],"Using a stepped-wedge randomized controlled trial, the study will test whether a clinic-level multidimensional intervention conducted in 36 opioid treatment programs (OTPs) will improve clinical decision making, regulatory confusion, legal liability concerns, capacity for clinical practice change, and financial barriers to take- home dosing (THD) for methadone as compared to treatment as usual.",[311],"Problems Related to Social Environment",{"date":270,"type":33},{"date":314,"type":33},"2023-01-27",{"date":316,"type":22},"2027-08-31",{"name":38,"class":39},4,{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":325,"enrollmentInfo":326,"targetDuration":4,"studyType":23,"phases":328,"briefSummary":329,"conditions":330,"keywords":332,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":40},"100481377","effect-of-2-week-continuous-glucose-monitoring-on-glycemic-management-in-patients-new-to-insulin-on-hospital-discharge-100481377","NCT05548205","Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge","Inclusion Criteria:\n\n1. Male or female aged 18-100 years\n2. Known history of type 1 or type 2 diabetes\n3. Admitted to NYU Langone Hospital - Long Island between December 16, 2024- December 31, 2026\n4. New initiation of insulin therapy, including basal insulin regimen, basal-bolus insulin regimen, or mixed insulin regimen at the time of hospital discharge\n\nExclusion Criteria:\n\n1. Prior to admission use of home insulin therapy\n2. Current use of systemic corticosteroids\n3. Active pregnancy; as pregnancy requires different blood glucose targets, subjects known to be pregnant will be excluded from this study. Subjects will not be tested for pregnancy outside of testing performed in routine medical care; pregnancy will be determined by patient self-reporting. Females of childbearing potential will not be instructed to avoid pregnancy, however if they became pregnant during the study (detected by self-reporting), they will be withdrawn from the study.","100 Years",{"count":327,"type":22},150,[25],"The proposed study will be a randomized, prospective, non-blinded study of 120 participants with type 1 or type 2 diabetes that are new-to-insulin on hospital discharge. On hospital discharge, participants will be assigned to either the intervention of wearing a continuous glucose monitor (CGM) for 2 weeks or blood glucose monitoring (BGM) for 2 weeks. They will have a 2-week follow up visit, during which insulin doses will be adjusted as needed, and a 3-month follow-up visit, at which point HbA1c will be measured.",[331],"Diabetes",[333],"Continuous Glucose Monitoring (CGM)","2026-08-06",{"date":336,"type":33},"2026-08-07",{"date":338,"type":33},"2024-12-16",{"date":340,"type":22},"2027-04-30",{"name":38,"class":39},{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":12,"sex":348,"minAge":49,"maxAge":349,"enrollmentInfo":350,"targetDuration":4,"studyType":284,"phases":4,"briefSummary":352,"conditions":353,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":40},"100607161","prospective-database-of-clinical-outcomes-following-cryotherapy-for-ablation-of-clinically-localized-prostate-cancer-100607161","NCT07184957","Prospective Database of Clinical Outcomes Following Cryotherapy for Ablation of Clinically Localized Prostate Cancer","Inclusion Criteria:\n\n* Evidence of focal prostate cancer confined to the prostate based on MRI imaging and prostate biopsy\n* Patients with clinically localized prostate cancer (no evidence for or concern for metastatic spread of cancer outside of the prostate) will be counseled regarding treatment options. Those selecting focal Cryo prostate ablation will then be offered inclusion into this data collection.\n\nExclusion Criteria:\n\n* Men that are not diagnosed with prostate cancer.\n* Men that are diagnosed with clinically localized prostate cancer, but select other treatment options as their desired treatment.","MALE","85 Years",{"count":351,"type":22},1000,"This will be a prospectively maintained research database. The purpose is to record baseline parameters and treatment outcomes following of Cryotherapy for ablation of clinically localized prostate cancer.",[354],"Prostate Cancer","2026-08-05",{"date":336,"type":33},{"date":358,"type":33},"2017-05-01",{"date":360,"type":22},"2040-12-31",{"name":38,"class":39},{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":101,"enrollmentInfo":369,"targetDuration":4,"studyType":23,"phases":371,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":375,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":4},"100536817","exercise-program-for-itb-syndrome-100536817","NCT06269757","Exercise Program for ITB Syndrome","Efficacy of an Individualized Exercise Program for Iliotibial Band Syndrome: A Randomized Controlled Study","Inclusion Criteria:\n\n* Clinical diagnosis of ITB syndrome\n* Age 18-65\n* Ability to comply with a standardized physical therapy protocol\n* Willing and able to provide consent\n\nExclusion Criteria:\n\n* Patients at any increased risk of falls or at increased risk from harm due to falling, including issues with vertigo, osteoporosis, or a history of past falls\n* Patient otherwise deemed at increased risk from this investigational rehabilitation program by their referring surgeon or physical therapist\n* Patients who are pregnant",{"count":370,"type":22},100,[25],"Patients with diagnosed iliotibial band (ITB) syndrome indicated for non-operative management will be randomized to individualized exercise program or standard physical therapy over the course of 3 months to determine any possible difference in clinical outcomes.",[374],"Iliotibial Band Syndrome",{"date":336,"type":33},{"date":377,"type":22},"2027-03-01",{"date":379,"type":22},"2027-10-01",{"name":38,"class":39},{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":348,"minAge":4,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":23,"phases":389,"briefSummary":391,"conditions":392,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":394,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":398,"locationsCount":318},"100520079","phase-4-assessing-optimal-xrb-initiation-points-in-jail-100520079","NCT06051890","Assessing Optimal XRB Initiation Points in Jail","Assessing Optimal Extended-Release Buprenorphine (XRB) Initiation Points in Jail","Inclusion Criteria:\n\n* Incarcerated men able to provide written informed consent in English.\\*\n* Unsentenced.\n* Entering the facility with a prescription for SLB and receiving SLB for at least the previous 3 days.\n* Minimum anticipated jail stay is 4 days.\n* Willing to accept being randomized to the experimental condition (i.e., transitioning to XRB while incarcerated).\n\nExclusion Criteria:\n\n* Sentenced.\n* Allergy, hypersensitivity or medical contraindication to either medication.\n* Chronic pain requiring opioid pain management or other contraindicated medications.",{"count":51,"type":22},[390],"PHASE4","This application describes a 3-year, randomized controlled trial. Eligible, consenting adults (N=200) with existing sublingual buprenorphine (SLB) prescriptions who enter Middlesex County House of Corrections (MCHOC) as pre-trial detainees will be randomized at admission on a 1:1 basis to be inducted onto extended-release buprenorphine (XRB) at the time of admission (experimental condition) or remain in SLB (E-TAU; all participants will also receive naloxone). The two approaches will be compared with regard to (1) the percentage of participants released from jail with at least 7 days of buprenorphine in their system, (2) percentage of participants continuing MOUD treatment in the community, and (3) infractions related to buprenorphine diversion.",[393],"Opioid Use Disorder",{"date":336,"type":33},{"date":396,"type":33},"2025-06-02",{"date":377,"type":22},{"name":38,"class":39},{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":406,"enrollmentInfo":407,"targetDuration":4,"studyType":23,"phases":409,"briefSummary":410,"conditions":411,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":417,"leadSponsor":418,"locationsCount":40},"100650306","phase-4-a-clinical-trial-of-antiplatelets-in-psoriasis-100650306","NCT07744191","A Clinical Trial of Antiplatelets in Psoriasis","A Randomized, Double-blind, Placebo-controlled Crossover Trial of Antiplatelet Therapies in Psoriasis","Inclusion Criteria:\n\n1. One of the following:\n\n   1. A history of psoriasis as confirmed by a board-certified dermatologist OR\n   2. A history of psoriatic arthritis as confirmed by a board-certified rheumatologist\n2. Age ≥ 18 \\& \\\u003C 90 years\n3. Able and willing to provide written informed consent for the study\n4. English-speaking unless a translated informed consent form is approved\n5. No previous antiplatelet or anticoagulant use for 14 days prior to enrollment\n\nExclusion Criteria:\n\n1. A prior history of a myocardial infarction, stroke\u002FTIA, or occlusive peripheral arterial disease\n2. Chronic antiplatelet\u002Fanticoagulant use that is not able to be stopped at least 14 days prior to study enrollment\n3. Uncontrolled hypertension resting systolic blood pressure \\> 180 mm Hg or diabetes HbA1c \\> 10%\n4. Known active cancer receiving treatment\n5. Pregnancy\n6. Anemia (hemoglobin \\\u003C 9 mg\u002Fdl) or thrombocytopenia (Platelet count \\\u003C75), or thrombocytosis (Platelet count \\>600)\n7. A history of severe bleeding or bleeding disorders\n8. Active gastrointestinal ulcer\n9. Active pathological bleeding.\n10. Chronic kidney disease (CrCl \\\u003C 30ml\u002Fmin)\n11. Congestive heart failure\n12. Known hypersensitivity to or allergy to aspirin, clopidogrel, or any of the components of the study capsules\n13. History of aspirin-exacerbated respiratory disease or asthma induced by salicylates or NSAIDs\n14. Currently breastfeeding\n15. Persons of childbearing potential unwilling to use acceptable contraception during the study","90 Years",{"count":408,"type":22},60,[390],"The purpose of this study is to determine the effect of antiplatelet therapy on the endovascular phenotype in psoriasis, specifically whether clopidogrel reduces vascular endothelial pro-atherosclerotic transcript expression more than aspirin or placebo. The primary endpoint is mean change in a composite endothelial pro-inflammatory\u002Fpro-atherosclerotic transcript expression signature measured from brachial vein endothelial cells.",[412,413],"Psoriasis (PsO)","Psoriatic Arthritis (PsA)","2026-08-03",{"date":355,"type":33},{"date":119,"type":22},{"date":172,"type":22},{"name":38,"class":39},{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":284,"phases":4,"briefSummary":428,"conditions":429,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":433,"completionDateStruct":434,"leadSponsor":435,"locationsCount":40},"100650434","central-line-associated-bloodstream-infection-qi-project-100650434","NCT07746674","Central Line-Associated Bloodstream Infection QI Project","Central Line-Associated Bloodstream Infection (CLABSI) Quality Improvement Project","CLABSI","Inclusion Criteria:\n\n* Not hospice patient class\n* Active central line for at least 24 hours\n\nExclusion Criteria:\n\n* No active central line\n* Central line present for less than 24 hours",{"count":21,"type":22},"This study evaluates a daily electronic health record (EHR) alert designed to reduce unnecessary central venous catheter (CVC) use among hospitalized adults. The alert identifies patients with an active CVC and no documented indication, prompting the first-contact provider to document line necessity. The study compares alert and a secure chat intervention to usual care, with the goal of reducing unnecessary line days and related CLABSI risk.",[430],"Central Line-associated Bloodstream Infection (CLABSI)","2026-07-31",{"date":355,"type":33},{"date":119,"type":22},{"date":193,"type":22},{"name":38,"class":39},{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":284,"phases":4,"briefSummary":445,"conditions":446,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":448,"startDateStruct":449,"completionDateStruct":450,"leadSponsor":451,"locationsCount":40},"100650394","ai-snf-discharge-quality-improvement-project-100650394","NCT07746648","AI SNF Discharge Quality Improvement Project","Artificial Intelligence (AI) Skilled Nursing Facilities (SNF) Discharge QI Project","AI SNF","Inclusion Criteria:\n\n* Adult medicine inpatient admission\n* Discharged to a skilled nursing facility\n* Admission occurs during the study period\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Not admitted to a medicine inpatient service\n* Not discharged to a skilled nursing facility\n* Admission occurs outside the study period",{"count":21,"type":22},"This study evaluates an AI-supported workflow tool designed to improve discharge planning for hospitalized medicine patients discharged to skilled nursing facilities (SNFs). The intervention displays a patient list column showing SNF discharge risk as High, Intermediate, or Low, along with a hover bubble containing AI-generated summaries of the history and physical note to provide relevant clinical context. The control condition hides the column value.",[447],"Skilled Nursing Facility Patients",{"date":355,"type":33},{"date":119,"type":22},{"date":193,"type":22},{"name":38,"class":39},{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":458,"eligibilityCriteria":459,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":284,"phases":4,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":464,"startDateStruct":465,"completionDateStruct":466,"leadSponsor":467,"locationsCount":40},"100650373","behavioral-emergency-response-team-bert-qi-project-100650373","NCT07746661","Behavioral Emergency Response Team (BERT) QI Project","Behavioral Emergency Response Team (BERT) Quality Improvement Project","BERT","Inclusion Criteria:\n\n* Adult inpatients aged 18 years or older\n* Admitted to participating hospital unit(s) during the study period\n\nExclusion Criteria:\n\n* Patients younger than 18 years\n* Patients not admitted to participating unit(s)\n* Patients admitted outside the 3-month implementation period\n* Encounters without sufficient clinical data to calculate or display a BERT prediction score",{"count":21,"type":22},"The BERT project will implement a clinical decision support tool that predicts which admitted patients are at higher risk of requiring a Behavioral Emergency Response Team (BERT) intervention within the next 48 hours. The model uses existing EHR data and displays a risk-stratified patient list in an Epic dashboard visible to providers for 3 months. The goal is to help clinicians identify high-risk patients earlier, prioritize behavioral health resources, and support proactive intervention planning before escalation occurs.",[463],"Hospital Inpatients",{"date":355,"type":33},{"date":119,"type":22},{"date":193,"type":22},{"name":38,"class":39},{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":475,"targetDuration":4,"studyType":23,"phases":477,"briefSummary":478,"conditions":479,"keywords":481,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":490},"100650034","kidney-rise-randomized-integrated-supportive-care-trial-100650034","NCT07741357","Kidney RISE: Randomized Integrated Supportive CarE Trial","Phase II Multi-Site Randomized Controlled Trial Testing Integrated Kidney Palliative Care Compared With Usual Chronic Kidney Disease Care (Kidney RISE)","Inclusion Criteria:\n\n1. Receive care at nephrology clinics or dialysis centers associated with each site.\n2. Have CKD stage IV, V (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m2), or be receiving chronic dialysis\n3. Speak Spanish or English, and report at IPOS-Renal score of ≥ 3 on a screening survey.\n4. Willing to be randomized to either study arm and to comply with the study procedures for the assigned group.\n\nExclusion Criteria:\n\n1. Unable to provide informed consent\n2. Has received palliative care (inpatient or outpatient) in the last six months.\n3. Enrolled in hospice\n4. Has any urgent palliative care needs (i.e. severe pain, emotional distress) identified upon screening. Research staff will be trained to recognize these needs.\n5. Non-English and Non-Spanish speakers to correspond with the populations most impacted by CKD in the US.\n6. Pregnant individuals.",{"count":476,"type":22},280,[25],"The purpose of study is to investigate whether adding palliative care to usual chronic kidney disease (CKD) care improves symptoms and quality of life for people with CKD. The primary objectives are to 1) determine efficacy of Kidney Palliative Care (KPC) integrated with CKD care on symptom burden compared with usual CKD care, 2) identify clinical and demographic factors associated with differential responses to KPC, and 3) characterize participant and provider experiences with kidney care and factors influencing implementation.",[480],"Chronic Kidney Disease (Stages 4 and 5)",[482],"CKD","2026-07-29",{"date":414,"type":33},{"date":486,"type":22},"2027-05",{"date":488,"type":22},"2031-01",{"name":38,"class":39},2,{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":498,"targetDuration":4,"studyType":23,"phases":499,"briefSummary":500,"conditions":501,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":40},"100606762","phase-1-effects-of-belzutifan-on-89zr-dfo-girentuximab-pet-uptake-in-patients-with-renal-cell-carcinoma-rcc-100606762","NCT07179770","Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)","A Phase 1b Study to Assess the Effects of Belzutifan on 89Zr-DFO-girentuximab Uptake as a Surrogate to Determine CAIX Tumor Expression in Patients With Clear Cell Renal Cell Carcinoma","Inclusion Criteria:\n\n1. Histologically confirmed advanced clear cell RCC\n2. Radiographic disease progression to prior immune checkpoint inhibitor (ICI) therapy for RCC\n\n   * ICI for adjuvant therapy: Patients who experienced radiographic tumor progression during or within 6 months after last dose of adjuvant ICI\n   * ICI for locally advanced or metastatic disease: radiographic disease progression during or following ICI treatment in the 1st line setting\n   * Minimum two previous treatment regimens but no maximum limit\n3. Measurable disease per RECIST v1.1\n4. Recovery to baseline or Grade1 NCI CTCAE v5.0 from toxicities related to any prior treatments, unless adverse events are clinically nonsignificant and\u002For stable in the opinion of the investigator.\n5. Age\\>18 years of age\n6. Karnofsky performance score ≥60%\n7. Patients must have adequate organ and marrow function as defined below:\n\n   * absolute neutrophil count ≥1,000\u002FmcL\n   * platelets ≥100,000\u002FmcL\n   * total bilirubin ≤ institutional upper limit of normal (ULN)\n   * Aspartate Aminotransferase (AST) (SGOT)\u002FAlanine Aminotransferase (ALT) (SGPT ≤3 × institutional ULN\n   * creatinine ≤ institutional ULN OR\n   * glomerular filtration rate (GFR) ≥60 mL\u002Fmin\u002F1.73 m2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL\u002Fmin\u002F1.73 m2\n\n     1. Patients with abnormal test results outside the allowable range, but are not clinically significant, may still enroll with PI's review and approval.\n     2. Laboratory reference values should account for potential normal variations due to race, ethnicity, age, sex, and gender identity (e.g., due to surgical and\u002For hormonal changes).\n8. Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.\n9. For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n10. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n11. Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.\n12. Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy.\n13. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n14. Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.\n15. Patients who agree to use an adequate method of contraception throughout the study period, starting with the administration of 89Zr-DFO-girentuximab,\n16. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> Grade 1) with the exception of alopecia.\n2. Patients who are receiving any other investigational agents.\n3. History of allergic reactions attributed to compounds of similar chemical or biologic composition to girentuximab.\n4. Patients with uncontrolled intercurrent illness at the discretion of the investigator.\n5. Pregnant women are excluded from this study because belzutifan is an agent with the potential for teratogenic or abortifacient effects.",{"count":152,"type":22},[105],"The purpose of this study is to identify changes in Carbonic Anhydrase IX (CAIX) expression induced by hypoxia-inducible factor 2 alpha (HIF-2α) inhibition by initiating belzutifan single agent therapy and imaging CAIX expression with 89Zr-DFO-girentuximab PET before and 4 weeks after initiating treatment. This will be the first study to evaluate potential changes in CAIX expression altered by belzutifan. Information gained from this study will be leveraged to develop combinations of belzutifan with CAIX targeted agents including radioimmunotherapy in the future.",[502],"Metastatic Clear Cell Renal Cell Carcinoma",{"date":504,"type":33},"2026-07-30",{"date":506,"type":33},"2025-09-15",{"date":508,"type":22},"2028-10-01",{"name":38,"class":39},{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":48,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":517,"targetDuration":4,"studyType":23,"phases":519,"briefSummary":520,"conditions":521,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":523,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":40},"100605776","enhancing-engagement-of-partners-in-research-100605776","NCT07166913","Enhancing Engagement of Partners in Research","Enhancing Stakeholder Engagement in Pediatric Research","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, PIs must oversee a study that meets the following criteria:\n\n1. Studies who either have not started enrollment or are within 1-3 months of the start of enrollment, and within the 25% ceiling for % recruitment target.\n2. Studies that have started enrollment must be no further than 25% of projected enrollment timeline of the study (with at least 6 months remaining for enrollment).\n3. Target n\\>50 participants in study.\n4. At least 10 stakeholder partners part of study. The PI's must also be ≥18 years old;\n\nIn order for study stakeholders to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. \\>=12 years old;\n2. Ability to speak either English, Spanish, or Chinese, and;\n3. Part of the study team or serving in an advisory capacity to the study team\n\nThe same criteria as that used for stakeholder and PI eligibility applies to Key informant (KI) interviews.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Not able to complete 6 month follow-up assessment\n2. Children who are wards\u002Ffoster children\n3. Not able or willing to provide consent.\n4. Concurrent enrollment in another study that is part of this research project.\n\nIn addition, PI's who meet the following criteria will be excluded from participation in this study:\n\n1\\. A lot of experience with stakeholder engagement (based on screener survey question)",{"count":518,"type":22},480,[25],"The purpose of this study is to examine the implementation and effectiveness of a bundle of engagement strategies for pediatric patient centered outcomes research (PCOR) studies. The study aims to examine the effectiveness of a \"bundle\" of enhanced engagement strategies on improved stakeholder engagement and study protocol indicators (including improved language access, meeting recruitment\u002Fretention goals) compared to standard practice.",[522],"Stakeholder Engagement",{"date":431,"type":33},{"date":525,"type":33},"2025-09-08",{"date":527,"type":22},"2027-12-01",{"name":38,"class":39},{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":348,"minAge":19,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":23,"phases":537,"briefSummary":538,"conditions":539,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":542,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":40},"100565105","sexual-and-urinary-function-improvement-for-cancer-survivors-100565105","NCT06637852","Sexual and Urinary Function Improvement for Cancer Survivors","Sexual and Urinary Function Improvement for Cancer Survivors- Promoting Access to Collaborative Treatment (SUFICS-PACT)","Inclusion Criteria:\n\n* At least 18 years old\n* Have a diagnosis of prostate cancer\n* Have sought care\u002Ftreatment for prostate cancer\n\nExclusion Criteria:\n\n* Patients under 18 years old\n* Patients who have not sought care\u002Ftreatment for prostate cancer\n* Patients who are categorized as \"vulnerable subjects,\" such as minors or incarcerated individuals.",{"count":72,"type":22},[25],"The purpose of this study is to test the efficacy of SUFICS-PACT to identify and treat sexual and urinary dysfunction in prostate cancer survivors at NYC H+ H\u002FBellevue, the oldest public hospital in the US. This study will evaluate the implementation of an adapted sexual and urinary function collaborative care model at NYC Health+Hospitals\u002FBellevue. The study will test the efficacy of this collaborative care model through a randomized controlled trial in the adult primary care clinic; the intervention arm will receive collaborative treatment consisting of a care manager who has specialty training in mental health and psychosexual counseling, a primary care nurse practitioner who leads symptom management, primary care physicians who supervise the team, and a team specialty consult liaison.",[540,541],"Urinary Dysfunction","Sexual Dysfunction",{"date":504,"type":33},{"date":544,"type":22},"2026-10-01",{"date":546,"type":22},"2030-03-31",{"name":38,"class":39},""]